Akèy › Lukemi lenfositè kwonik › Oklahoma
Etid klinik pou Lukemi lenfositè kwonik nan Oklahoma
4 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 65 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT04269902A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06428019Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.